

Title (en)
CONJUGATES COMPRISING CYTOKINES AND NUCLEIC ACIDS FOR TREATING PROLIFERATING CELLS

Title (de)
KONJUGATE AUS ZYTOKINEN UND NUKLEINSÄUREN ZUR THERAPIE VON ZELLPROLIFERATION

Title (fr)
PRODUITS DE THERAPIE GENIQUE

Publication
EP 1185304 A2 20020313 (EN)

Application
EP 00935338 A 20000605

Priority
• GB 0002014 W 20000605
• GB 9912807 A 19990603
• US 13759299 P 19990603

Abstract (en)
[origin: WO0074724A2] A product comprising a proliferatively active moiety linked to genetic or nucleic acid material which is associated with protective material. The proliferatively active moiety is typically a cytokine or growth factor. The protective material may form a micelle, especially a liposome, which may encapsulate the nucleic acid material or be positively charged and hold the nucleic acid on its surface (a so-called lipoplex). One class of protective materials, therefore, comprises complexing materials and includes not only cationic liposomes but also other cationic materials, especially polymers. As suitable polymers there may be mentioned polylysine (especially poly-D-lysine), polylysine derivatives (e.g. phospholipid derivatives of, in particular, poly-L-lysine) and polyethyleneimine (PEI). Other suitable complexing agents are dendrimers, especially polyamidoamine dendrimers (which are cationic). The genetic or nucleic acid material may be a cytotoxic gene, a defect correction gene or an immunogene. Suitable cytotoxic genes are for expressing an enzyme to convert a prodrug into a toxic drug.

IPC 1-7
A61K 48/00

IPC 8 full level
A61K 9/107 (2006.01); **A61K 9/127** (2006.01); **A61K 31/7088** (2006.01); **A61K 38/00** (2006.01); **A61K 38/20** (2006.01); **A61K 38/22** (2006.01); **A61K 38/27** (2006.01); **A61K 38/43** (2006.01); **A61K 38/44** (2006.01); **A61K 38/45** (2006.01); **A61K 38/46** (2006.01); **A61K 47/24** (2006.01); **A61K 47/42** (2006.01); **A61K 47/48** (2006.01); **A61K 48/00** (2006.01); **A61P 1/02** (2006.01); **A61P 1/04** (2006.01); **A61P 1/16** (2006.01); **A61P 3/10** (2006.01); **A61P 5/14** (2006.01); **A61P 7/00** (2006.01); **A61P 7/04** (2006.01); **A61P 7/06** (2006.01); **A61P 13/12** (2006.01); **A61P 17/00** (2006.01); **A61P 17/06** (2006.01); **A61P 21/00** (2006.01); **A61P 25/28** (2006.01); **A61P 27/02** (2006.01); **A61P 29/00** (2006.01); **A61P 31/12** (2006.01); **A61P 31/14** (2006.01); **A61P 31/18** (2006.01); **A61P 35/00** (2006.01); **A61P 35/02** (2006.01); **A61P 37/04** (2006.01); **A61P 37/06** (2006.01); **A61P 37/08** (2006.01); **A61P 43/00** (2006.01); **C07K 14/52** (2006.01); **C12N 15/09** (2006.01); **C12N 15/87** (2006.01)

CPC (source: EP)
A61K 38/2013 (2013.01); **A61K 47/642** (2017.07); **A61K 47/645** (2017.07); **A61K 47/6455** (2017.07); **A61K 47/6907** (2017.07); **A61K 47/6911** (2017.07); **A61K 47/6929** (2017.07); **A61K 48/00** (2013.01); **A61P 1/02** (2017.12); **A61P 1/04** (2017.12); **A61P 1/16** (2017.12); **A61P 3/10** (2017.12); **A61P 5/14** (2017.12); **A61P 7/00** (2017.12); **A61P 7/04** (2017.12); **A61P 7/06** (2017.12); **A61P 13/12** (2017.12); **A61P 17/00** (2017.12); **A61P 17/06** (2017.12); **A61P 21/00** (2017.12); **A61P 25/28** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 31/12** (2017.12); **A61P 31/14** (2017.12); **A61P 31/18** (2017.12); **A61P 35/00** (2017.12); **A61P 35/02** (2017.12); **A61P 37/04** (2017.12); **A61P 37/06** (2017.12); **A61P 37/08** (2017.12); **A61P 43/00** (2017.12); **C07K 14/52** (2013.01); **C12N 15/87** (2013.01)

Citation (search report)
See references of WO 0074724A2

Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT

DOCDB simple family (publication)
WO 0074724 A2 20001214; **WO 0074724 A3 20010712**; AU 5088600 A 20001228; EP 1185304 A2 20020313; JP 2003501402 A 20030114; MX PA01012500 A 20031014

DOCDB simple family (application)
GB 0002014 W 20000605; AU 5088600 A 20000605; EP 00935338 A 20000605; JP 2001501258 A 20000605; MX PA01012500 A 20000605